In a bid to maintain its dominance in the HIV market, Gilead Sciences (GILD) allegedly conspired with other drug makers whose medicines were part of a so-called combination cocktail in order to block generic competition, according to a lawsuit filed by AIDS activists and two unions.
Trending:
Gilead struck anti-competitive deals to bolster profits on an HIV drug, lawsuit says